KARO PHARMA TRIPLES SALES AND PROFIT IN THE SECOND QUARTER
INTERIM REPORT JANUARY – JUNE 2018 THE PERIOD AND THE SECOND QUARTER · Net sales amounted to MSEK 756.5 (281.8), of which the second quarterly MSEK 489.4 (142.5). This corresponds to an increase of 168.5%, and for the second quarter of 243.5%. Growth was driven mainly by acquisitions. · Organic growth during the period amounted to + 7.7%, and to + 4.3% in the second quarter. During the period, pharmaceuticals accounted for + 9.3% and other products for + 6.5%. · EBITDA amounted to MSEK 321.0 (93.5), of which the second quarter amounted to MSEK 232.3 (49.7), corresponding